FierceBiotech18h
Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
FierceBiotech22h
Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches
Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...
FierceBiotech10h
NIH grants up to $100M yearly for pandemic preparedness network
With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National ...
FierceBiotech19h
Awaiting FDA review, Medtronic details study of adaptive neurostimulation in Parkinson’s disease
Medtronic is offering a peek into its ongoing, at-home trial of people with Parkinson’s disease being treated with adaptive ...
FierceBiotech16h
GE HealthCare claims FDA clearance for amyloid imaging software in Alzheimer’s disease
GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...
FierceBiotech18h
ESMO: Innovent links cytokine fusion protein to responses in colorectal cancer
Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.
FierceBiotech19h
FDA scraps adcomm for Applied's rare disease drug ahead of November decision
After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...